Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 7.1
edited by manuelmenendez
on 2025/01/27 23:21
Change comment: There is no comment for this version
To version 9.1
edited by manuelmenendez
on 2025/01/27 23:23
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -15,7 +15,7 @@
15 15  (((
16 16  = What is this about and what can I find here? =
17 17  
18 -==== **Overview** ====
18 +== **Overview** ==
19 19  
20 20  The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
21 21  
... ... @@ -29,7 +29,7 @@
29 29  * Integration of incomplete datasets using AI-driven probabilistic modeling.
30 30  * Stratification of patients for personalized treatment.
31 31  
32 -==== **Diagnostic Axes** ====
32 +== **Diagnostic Axes** ==
33 33  
34 34  * (((
35 35  **Axis 1: Etiology**
... ... @@ -53,28 +53,11 @@
53 53  * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
54 54  )))
55 55  
56 -==== **Case Studies** ====
56 +== **Applications** ==
57 57  
58 -1. (((
59 -**Sporadic Alzheimer’s Disease**:
60 -
61 -* Axis 1: Sporadic (ApoE4, poor sleep habits).
62 -* Axis 2: Amyloid-beta plaques, elevated NFL.
63 -* Axis 3: Right hippocampus atrophy (visual memory loss).
64 -)))
65 -1. (((
66 -**Genetic Parkinson’s Disease**:
67 -
68 -* Axis 1: Genetic (LRRK2 mutation).
69 -* Axis 2: Alpha-synuclein aggregation.
70 -* Axis 3: Substantia nigra degeneration (motor dysfunction).
71 -)))
72 -
73 -==== **Applications** ====
74 -
75 75  This system enhances:
76 76  
77 -* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
60 +* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
78 78  * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
79 79  
80 80  == Who has access? ==